Publications by authors named "Marin Kursar"
Article Synopsis
- This review focuses on summarizing the current first-line treatments for nodal T-cell non-Hodgkin lymphoma.
- The standard CHOP chemotherapy has shown poor results, but recent advancements like the ECHELON-2 trial suggest that adding brentuximab vedotin could improve outcomes for certain subtypes of the disease.
- Other promising developments include increased use of autologous stem cell transplantation for better disease control, though CHOP remains the primary treatment while new trials are exploring alternative options.
- The aim of this review is to present data on bendamustine, a non-cross resistant alkylating agent, alone or in combination for treatment of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Bendamustine is currently approved for rituximab-resistant indolent NHL and CLL in patients not fit for conventional chemotherapy. Recent studies have shown superiority of bendamustine combination with rituximab (B-R) in first line treatment of indolent NHLs and mantle cell lymphoma, suggesting a shift of the standard of care in this setting.
View Article and Find Full Text PDFECHELON-1 study is a randomized open-labeled controlled trial investigating whether addition of brentuximab vedotin to chemotherapy offers benefit over the standard chemotherapy regimen in advanced Hodgkin lymphoma. After a median follow-up of 24.6 months, it has met its primary endpoint the reduction of modified progression-free survival being 23 percent.
View Article and Find Full Text PDFBackground: The prevalence of asthma and allergic diseases in children has been increasing worldwide over the past decades. The ISAAC Phase I results supplies valuable information on the worldwide variations in the prevalence of these diseases. Although ISAAC Phase I was completed in 56 countries, not all regions of Croatia were covered.
View Article and Find Full Text PDF